| Serial Number | 97730294 |
| Word Mark | NYXROSI |
| Filing Date | Friday, December 23, 2022 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Monday, September 30, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 13, 2024 |
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, December 29, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Turning Point Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Party Name | Turning Point Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Event Date | Event Description |
| Thursday, December 14, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, December 27, 2022 | NEW APPLICATION ENTERED |
| Thursday, December 29, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, September 23, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, September 27, 2023 | NON-FINAL ACTION WRITTEN |
| Wednesday, September 27, 2023 | NON-FINAL ACTION E-MAILED |
| Wednesday, September 27, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, December 14, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, December 15, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, January 8, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Tuesday, February 13, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, February 13, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 9, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Monday, September 30, 2024 | SOU TEAS EXTENSION RECEIVED |
| Monday, September 30, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, September 30, 2024 | SOU EXTENSION 1 FILED |
| Monday, September 30, 2024 | SOU EXTENSION 1 GRANTED |
| Wednesday, January 24, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |